We crossed $3B in revenue managed by Cora agents just months after launch... so we hopped on a plane to hear from customers on the outcomes Cora is driving.
Some of the highlights we heard:
→ @HeyGen reactivated hundreds of dormant customers, with direct impact to net dollar retention
→ @BetterUp saw 5,000 hours and at least a million dollars saved from automating manual work
→ Flock re-engaged thousands of long-tail customers with personalized touch
yes. imo this is the problem frontier labs should be pointing the war chest at. massive commercial surface, clearest public good (alongside “cure cancer”)…
curious how much F1000 buyers are prioritizing this in board rooms vs rolling out automation to cut another cost center. feels so much more urgent.
1/ pretty bad out there. We have to fix the last 50 years of software and internet sloppiness. Faster than adversaries can find the holes, and faster than we ship new ones (with agents!). CVEs went from ~4k a month to ~15k since April. That is not business as usual.
3
120
the future is going to be so cool
Today we announced the Claude-led discovery of a molecular machine that we suspect could represent a new gene editing mechanism. Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is work I would have been proud to do as a PhD student. The work was done mostly, though not entirely, by Claude: our life sciences team suggested a broad area of research, Claude read through the literature and a bunch of genome data and discovered something interesting, then Claude proposed experiments to verify the discovery and our team carried them out.
It’s easy to dismiss this as a one-off or curiosity, but we’ve repeatedly seen a pattern where AI performance in new intellectual domains goes from weak to superhuman in a matter of a few years. In 2023 models struggled to do math at the level of an average high-school student. In 2024 they started to do well on math competitions for the best high-schoolers in the country, in 2025 they started to solve minor open problems, in early 2026 more significant open problems, and in late 2026 they are beginning to solve the top few open problems in all of mathematics. We believe AI for biology is on a similar exponential trend.
The main difference between biology and mathematics, of course, is that math can be done purely theoretically, while biology requires experimentation. Some have used this to draw the conclusion that AI’s utility in biology will be limited. We think this is wrong. As we’ve demonstrated today, humans can collaborate with AI to perform the experiments, validate key results in a few weeks and, if necessary, work with the AI to iterate on what they find. Eventually it may even be possible for Claude itself to safely perform the experiments by autonomously controlling lab equipment, with appropriate safeguards in place, but we aren’t doing that today (our lab is also a BSL1/BSL2 facility that doesn't handle materials dangerous to humans).
More broadly, biomedical advancement has many stages — from fundamental biology discoveries, to translational research, to drug discovery, clinical trials, and finally the actual delivery of medicines and health care to patients. We are also interested in these later stages, but even simply accelerating the first stage of fundamental biological discoveries has the potential to speed up and broaden the entire pipeline. Improving our understanding of biology and sharpening biologists’ tools can drive forward all of the later stages, for example by identifying new drug targets, finding new therapeutic modalities, allowing for more precise measurement, and speeding up the experimental loop which itself further accelerates our understanding of biology. This will not in itself speed up clinical trial times, but if it succeeds it could greatly increase the number of promising candidates that go into the pipeline — an increase in throughput even though latency remains.
In Machines of Loving Grace, I wrote about AI’s potential to “cure most diseases in 5-10 years” — a goal that sounds impossible, but one I believe is just barely possible if AI is applied to every stage of the pipeline. The first step is showing that AI can first help with, and then drive, biological discoveries.
Claude’s discovery is the latest in a line of related prior work that goes back decades, beginning with systems like CRISPR, and continuing with discoveries like the bridge recombinase and VIPR in the past few years. Recently, there has been heightened interest in systems based on reverse transcriptase (RT) enzymes, the enzyme underlying the system Claude identified. And most recently, a Stanford team working independently described a novel RT system with an associated non-coding array that is in some ways similar to the one Claude found, though they are distinct systems that evolved independently from each other. I believe that we’re at the very beginning of finding such systems and developing them into powerful tools for biotechnology.
I’m proud of the resources Anthropic has invested in accelerating the public benefits of AI through the life sciences, and we’re aiming both to grow our life sciences team and to work with other scientists to extend this approach to a broad range of problems. If you have a proposal for a research collaboration or are interested in joining our life sciences team, please reach out.
1
50
unsurprisingly my killer Muse use case is... shopping.
maybe because i'm furnishing a new place, but Muse (previously Instinct) has become my #1 destination for virtually all my non-work screen time these days.
keep seeing hot takes that people outside of tech twitter don't need ai personal assistants and i think most are underestimating how massive the market is for just buying and selling stuff/services/experiences.
yes the average person will not have personal agents running complex automations to run their life..
but they will have an agent helping them find/buy that exact rug from that influencer's instagram post and helping them sell the dining room chairs they don't like anymore on facebook marketplace.
hard to see how anyone is better positioned to win this race other than Meta.
2
2
166
overheard in the office: “instinct has made claude feel old school and i didn’t think that was possible”
what a time to be alive
3
70
congrats @RohanPunamia! bluebirds acquisition paying off
Welcome Hunter, Salesforce’s new outbound sales agent. She built $500M in pipeline last quarter. See her work at Dreamforce. #DF26
1
119
it's so easy to de-slop your ai slop that it personally offends me when someone doesn't even bother
1
2
155
what stage of the singularity are we in when your anthropic friends start deleting their linkedins
7
1,276
one day we will look back and laugh at the mania of H1 2026 when we thought Claude would eat every app layer company
THE LABS WON'T WIN THE APP LAYER
@mignano (Mike Mignano), General Partner, Union Square Ventures, interviewed by @HarryStebbings (@20VC)
Summary: Mignano's argument is that the AI infrastructure buildout is largely finished, and value now shifts to the application layer, the way broadband once gave way to internet apps. He thinks the frontier labs cannot capture that layer, because markets rarely crown a single winner and specialized startups keep beating incumbents at the hard, regulated, context-rich problems. The takeaway for builders: move first, stay mission-driven, and spend tokens like the advantage they are.
1. The App Layer's Turn. The infrastructure is built, and now the applications get built on top of it. Mignano compares this moment to the early internet, when fiber and broadband were laid down and then an application layer arrived to use them. Trillions in value came from the labs' buildout, but the next wave is software, and there will be so much of it that you cannot place a bet unless you know exactly what you are looking for. That is the whole case for a thesis-driven fund over a consensus-driven one.
2. Obliterate, Don't Automate. USV backs companies that reinvent how something works, not ones that make an existing process incrementally faster. The example is Doctronic, which USV seeded on the idea of putting an AI doctor in everyone's pocket rather than helping practices process insurance claims. Automating a workflow usually means selling to a middleman and making incumbents a bit faster. Reinventing the model is where the enormous outcomes live.
3. Token Maxxing. If Mignano ran a startup today, he would still pound the table to maximize token spend on the things that matter, especially coding. A great engineer will pick the startup that says spend whatever you need on frontier models over an incumbent that hands them a constrained budget. Big companies like Salesforce, Microsoft, Meta, and Uber have to rein in spend because they carry tens of thousands of employees; a startup does not. Token spend is an advantage, and a small team should use every dollar of it against a giant.
4. The 3.8% Question. The entire bull case for Anthropic comes down to what share of developer salaries gets spent on tokens. Marc Benioff spent $300 million with Anthropic on his dev team, which works out to roughly 3.8% of those salaries. If that figure climbs toward 20% or 100%, Anthropic is wildly undervalued and its exponential revenue holds; if it stalls or spend migrates to open models, the story changes completely. One ratio decides whether the most valuable private company in the world is cheap or expensive.
5. Frontier Only For Code. Roughly 80% of non-coding enterprise tasks can run on models that are nowhere near the frontier. Summarization, drafting docs, and routine operations do not need the best model; coding does. That split creates room for a routing layer that sends each job to the model with the best price-to-capability fit. Open-source models are catching up fast enough that the frontier is only worth paying for when the work demands it.
6. The Rebel Alliance. Mignano is planting USV's flag in open-weight models, open harnesses, distributed compute, and human-aligned agents. Teams go where the incentives are, and as open options become genuinely competitive, smart teams drift toward them. China's open-source ecosystem is evolving at a startling rate, which pulls even more talent into the open camp. Publishing a thesis like this is a bat signal that tells the right founders who to call.
7. Who Is Your Agent Working For. As people hand agents their credit cards, their messages, and their agency, they will start asking whose incentives the agent actually serves. A lab's model is built to make the lab's model smarter, and a user may want a harness aligned with their own goals instead. Not everyone has to care about this for it to matter; enough people caring keeps a few good actors honest and holds the rest in check. Alignment with the user turns into a product feature and a real reason to pick one harness over another.
8. The 30% Rule. Markets almost never hand one company the whole thing; the winner usually takes about 30% and leaves 70% up for grabs. Coding assistants prove it, with Cursor, Lovable at $500 million in revenue, and Cognition all thriving at once. Anthropic put a whole team on design to go at Figma, and Figma still does billions with a trusted brand intact. Mignano changed his mind on this in the past year: even the biggest labs cannot do everything, just as Google and Apple never did.
9. The Context Moat. The durable advantage in AI products is the context they build up once they are inside an organization. Granola wins by doing one thing, meeting notes, and doing it best, which gets its foot in the enterprise door without asking anyone to rip out Gmail or Docs. Once a company's history of notes lives in the product, nobody wants to give that context up. Being first and staying focused is how a startup builds a moat that even Microsoft's bundling struggles to pry loose.
10. The Energy Floor. No matter which model wins, intelligence runs on power, so USV has been betting on energy since 2021. The portfolio includes Radiant's factory-line small nuclear reactors, Fuse, and Rune's micro data centers that sit next to wind farms to solve energy portability. These bets are capital-intensive at scale but cheap in the earliest days, when a team is running science experiments before anyone else is paying attention. The edge of energy innovation is exactly where a venture investor should place early bets.
11. Founder Over Market Over Product. Mignano used to rank product first; now he ranks founder, then market, then product. Early startups almost always pivot, so what matters most is whether the founder is resilient, can execute, and can adapt. The trait he underweighted is communication, which touches recruiting, fundraising, product vision, and storytelling to the market. A founder who cannot communicate cannot align a team or raise the capital to build.
12. Price As A Litmus Test. Fred Wilson's rule is never pass on price, and Mignano now uses price as a test of his own conviction. For the best founders, you would pay double and still feel good about it in hindsight. His hardest lesson as a former operator was to stop projecting his own plan onto founders, because even when your plan is right, it is their company and betting on your version is how you misjudge the team. The discipline is to trust the founder's judgment, and to let price tell you how much you actually believe.
1
6
818
Amir Ghowsi retweeted
I have seen how they built this, and it is one of the best examples of applying good taste to agentic business flows.
You can be a company that adds high risk agents like OpenClaw, or you can offload autonomy to a team that gets it.
It's time to break-up with the old way of running post-sales.
@cora_ai - the first proactive AI agents for customer success.
Winning the deal is just Day 0. Cora is the AI for everything that comes next.
Amir Ghowsi retweeted
I can't speak to the product itself (not my area of expertise). But @a_ghowsi is one of the kindest people I've ever met, and he still manages to be an absolute weapon.
I remember watching his insane rise through the product ranks at BetterUp. After every promotion I'd think "surely he can't do it again" and then he'd go and do it again.
I'm particularly bullish on @cora_ai because it's based on his "earned secrets" -- all the problems Amir had to solve during his time at BetterUp. When you live a problem-space for years, you can map all the tiny nooks and crannies in a way that more naive approaches might miss.
Also, the product-founder fit is just really good here. Somehow, especially for the last few months, Amir has been so good about proactively reaching out to me about exactly what's on my mind. The timing is honestly uncanny...
Anyway, if this product seems relevant to you, you should check it out. And if it doesn't, you should just watch the video -- even in this era of overproduced launch videos, this one made me laugh.
It's time to break-up with the old way of running post-sales.
@cora_ai - the first proactive AI agents for customer success.
Winning the deal is just Day 0. Cora is the AI for everything that comes next.
Amir Ghowsi retweeted
Very excited for what @cora_ai brings to companies who have historically been reactive, fragile and, honestly, confused on what needs to be done AFTER the sale. Congrats @a_ghowsi @jesalg and team!
It's time to break-up with the old way of running post-sales.
@cora_ai - the first proactive AI agents for customer success.
Winning the deal is just Day 0. Cora is the AI for everything that comes next.
Amir Ghowsi retweeted
Excited to introduce the world to Cora.
@a_ghowsi and I have spent our careers scaling B2B companies. We've tried every post-sales solution out there. Support chatbots, customer success platforms, and custom internal tools.
But in the B2B world, a reactive support chatbot won't save your customer relationship. Neither will more dashboards and CRM fields.
Now we have Cora.
It's time to break-up with the old way of running post-sales.
@cora_ai - the first proactive AI agents for customer success.
Winning the deal is just Day 0. Cora is the AI for everything that comes next.
















